ETFsBloomberg MSCI ESG US Corporate High Yield Select Index
Amundi

Amundi USD High Yield Corporate Bond ESG UCITS ETF EUR Hedged Dist

LYXE XETRADistributingPhysical, full replicationLuxembourgNot PEA-eligible
Last close · EUR
73.38EUR
0.00% · +€0.00
Published closes: 4 Nov 2026 - 5 Nov 2026
5 Nov 2026, close
LYXEBase
Fund charges
0.30%Total expense ratio (TER)
Fund size
€184.9Mall share classes
Return 1Y
-0.2%
Sharpe 3Y
0.13
Volatility 1Y
3.7%annualised
Holdings
788Fund holdings

Performance

Compare
  • LYXE-0.2%
  • Price, EUR

Returns

Returns1M3M6MYTD1Y3Y5Y
LYXE+0.7%-2.3%-1.9%-1.5%-0.2%+10.9%-9.8%
MSCI World-2.8%-0.6%+7.8%+14.0%+14.1%+65.6%+64.8%
Gap to MSCI World+3.5%-1.7%-9.7%-15.5%-14.3%-54.7%-74.7%

Risk and return

Sharpe ratio · 3Y
0.13
Below MSCI World · 1.24
Return p.a.
+3.3%
Volatility
4.8%
Max loss
-5.9%Dec 2023

Sharpe vs indices

MSCI World
1.24
S&P 500
1.21
STOXX Europe 600
1.04
MSCI Emerging Markets IMI
0.93
CAC 40
0.37
LYXE
0.13
Method

Weekly EUR returns from adjusted closes. Sharpe is the annualised excess return over the euro overnight rate (Xtrackers II EUR Overnight Rate Swap UCITS ETF 1C) divided by its volatility. Max loss uses daily closes.

Top holdings

Top 10
6.1%
Holdings
788
As of
Fund holdings
  1. 11261229 BC LT 1% Apr32US68288AAA511.06%
  2. 2SOFTBANK GRP 9.25% Apr32US83408KAB520.87%
  3. 3SOFTBANK GRP 9.75% Apr34US83408KAC360.77%
  4. 4NEXSTAR MDIA 6.5% Sep33US65346UAB520.57%
  5. 5SKYDANCE CORP 8.25% Oct31US69932AAN540.57%
  6. 6CENTENE CORP 4.625% Dec29US15135BAT890.55%
  7. 71011778 BC UL 4% Oct30US68245XAM110.46%
  8. 8DAVITA INC 4.625% Jun30US23918KAS780.44%
  9. 9LEVEL 3 FIN I 7% Mar34US527298CN120.43%
  10. 10MEDLINE BORRO 5.25% Oct29US62482BAB800.42%

Countries

Classified 99.2%
Largest
84.8%United States
Top 3
93.4%
Effective number
1.41 / HHI

Market cap

Weight vs holdings

6.1%of the fund sits in the top 10 holdings
  • Holdings 1-10
  • Holdings 11-50
  • Holdings 51-200
  • Holdings 201+

Size split

Not published

Compare ETFs in Copio.

ETF comparison in the Copio app, showing costs and returns with illustrative data.

Factual research, without a suitability score or investment recommendation. Past relationships can change.